Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Nutraceuticals (Bergamot 450 mg, Gymnema (400 mg, Phaseolamin 30 mg, Olea Europaea 10 mg) in Patients With Diabetes Mellitus Type II and Dyslipidemia.

NCT03676309 is registered in ClinicalTrials.gov with Villa dei Gerani as lead sponsor.

NCT NCT03676309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03676309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Nutraceuticals (Bergamot 450 mg, Gymnema (400 mg, Phaseolamin 30 mg, Olea Europaea 10 mg) in Patients With Diabetes Mellitus Type II and Dyslipidemia.
Lead sponsor
Villa dei Gerani
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2017
Completion date
March 26, 2018
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, nutritional and metabolic diseases, therapy-related morphologic change, vascular system injury